Canopy Clinical Research to Attend ADA Scientific Sessions & BIO International Convention

At Canopy Clinical Research, we’re always looking for opportunities to connect, collaborate, and contribute to the advancement of healthcare innovation and this year, we’re thrilled to be attending two of the industry’s most impactful events: the American Diabetes Association (ADA) Scientific Sessions and the BIO International Convention.

Accelerate your metabolic pipeline with Canopy Clinical - Meet us at ADA

June 5th – 8th 2026

The ADA Scientific Sessions are a cornerstone event for professionals dedicated to advancing diabetes research, care, and treatment. Bringing together leading clinicians, researchers, and industry innovators from around the world, the conference provides a powerful platform for sharing the latest breakthroughs and shaping the future of diabetes care.

As a clinical research partner committed to improving patient outcomes, we’re excited to engage in meaningful discussions around emerging therapies, trial design, and patient-centric approaches in diabetes research. These conversations are critical to accelerating progress and we’re proud to be part of them.

Connecting at the BIO International Convention

June 22nd – 25th 2026

We’re equally excited to attend the BIO International Convention, one of the largest global gatherings for the biotechnology industry. This event brings together leaders across biotech, pharma, investment, and research to foster partnerships that drive innovation forward.

For Canopy, BIO is an incredible opportunity to connect with sponsors, CRO partners, and emerging biotech innovators who share our commitment to high-quality, efficient clinical trial execution. We’re eager to exchange ideas, explore new collaborations, and support the development of transformative therapies across a range of therapeutic areas.

Sometimes, numbers speak louder than words:

Behind these numbers is a pre-screened database of 38,000+ participants, supported by a dedicated central recruitment and retention team, focused on keeping studies on track from first contact through to completion.
195
participants randomised in just 2.5 weeks
on a recent Phase 3 metabolic study
180
of 200 slots randomised
in a GLP-1 obesity trial
1st
site globally to screen and randomise
in a recent metabolic program
38K
in Participant Database
6
6 Site Locations
Across NSW and Victoria
3M
population
in catchment area
20+
CRO partners

The Canopy Edge

At Canopy Clinical, we take the time to truly listen to our customers specific needs, goals, and barriers. We craft tailored solutions to support your drug pipeline that are flexible, scalable, efficient, and cost-effective.
Quality of Results
At Canopy Clinical, we are deeply committed to maintaining the highest standards of quality and ethics in every aspect of our work. Participant safety and data integrity underpin everything we do. Our quality framework is focused on the issues that matter, driving agile and creative solutions.
Fast Activation
We understand time is key for every study. Through our streamlined central study-start up process, Canopy Clinical can initiate studies at speed, while always ensuring operational excellence.
Dedicated Recruitment and Retention Team
We have a strong track record in meeting and exceeding our recruitment targets. On all trials performed to date, we have met or exceed targets >90% of the time and have been the top recruiter for 80% of these trials.
Clinical Leadership
At Canopy Clinical, our clinical leadership framework is built on the expertise and insight of our Chief Medical Officer and team of experienced investigators.

Our team of principal and sub investigators have extensive experience in clinical trials for both healthy and complex patient studies, spanning Phase I through to Phase III.

Ability to Pivot
We are nimble and responsive and will adapt quickly to meet your changing needs. Our network approach allows us to scale and redirect resources to where they are needed most, ensuring your timelines are met and your study stays on track.
Cost-Effective
At Canopy Clinical, we are committed to delivering cost-effective solutions, without compromising on quality. Our network of trial sites allows us to streamline operations and resource allocation, reducing costs and increasing operational efficiencies.

Why Australia?

The clinical trial process and governing regulatory frameworks can be challenging to navigate. Pharmaceutical and biotechnology companies are focused on minimising risks - in particular, delays in drug development, to ensure timely market access.

Australia is one of the leading destinations globally for companies looking to outsource their early phase clinical trials. There is a myriad of benefits in outsourcing early phase clinical trials to Australia, including:

Cost
The Australian Federal Government offers substantial R&D tax incentives, including cash rebates.
Speed
The clinical trial process and regulatory pathway in Australia provides companies with a lot of flexibility, without compromising on quality. The Australian Clinical Trials Notification Scheme is global best practice in reducing regulatory requirements and trial lengths 
Quality
Australia is home to some of the most highly regarded research investigators, medical research institutes, universities, and clinical trial networks. Clinical data in Australia is compliant with the highest international standards and is recognised by US FDA/EMEA.  
Recruitment
Australian demographics are diverse, accessible and aligned to major European and US markets. Northern hemisphere sponsors can conduct trials year-round by taking advantage of Australia’s counter flu and allergy seasons 

Connect with Canopy Clinical

*